From: Lack of MMP-9 expression is a marker for poor prognosis in Dukes’ B colorectal cancer
Clinicopathological | Patients | Cumulative 5-year | χ2 | p-value | |
---|---|---|---|---|---|
variable | (n) | % | survival % | statistic | |
MMP2 immunoreactivity | 581 | 0.507 | 0.477 | ||
Negative | 256 | 44.1 | 58.8 | ||
Positive | 325 | 55.9 | 56.0 | ||
MMP8 immunoreactivity | 548 | 0.129 | 0.719 | ||
Negative | 119 | 21.7 | 56.6 | ||
Positive | 429 | 78.3 | 58.8 | ||
MMP9 immunoreactivity | 558 | 5.923 | 0.015* | ||
Negative | 208 | 44.9 | 52.2 | ||
Positive | 350 | 55.1 | 62.5 | ||
Gender | 619 | 0.000 | 0.992 | ||
Female | 289 | 46.7 | 56.1 | ||
Male | 330 | 53.7 | 57.5 | ||
Age | 619 | 7.777 | 0.005* | ||
< 65 years | 259 | 41.8 | 61.6 | ||
≥ 65 years | 360 | 58.2 | 53.4 | ||
Dukes’ stage | 619 | 293.83 | <0.001* | ||
A | 91 | 14.7 | 90.3 | ||
B | 222 | 35.9 | 77.7 | ||
C | 161 | 26.0 | 51.1 | ||
D | 145 | 23.4 | 8.7 | ||
Differentiation (WHO grade) | 618 | 18.982 | <0.001* | ||
1 | 19 | 3.1 | 83.1 | ||
2 | 406 | 65.7 | 60.9 | ||
3 | 165 | 26.7 | 46.3 | ||
4 | 28 | 4.5 | 41.3 | ||
Histologic type | 619 | 1.311 | 0.252 | ||
adenocarcinoma | 539 | 87.1 | 58.1 | ||
mucinous carcinoma | 80 | 12.9 | 48.6 | ||
Tumour location | 616 | 2.126 | 0.145 | ||
Colon | 339 | 55.0 | 58.3 | ||
Rectum | 277 | 45.0 | 55.4 | ||
missing | 3 |